Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Rational Design and Optimization of m6A-RNA Demethylase FTO Inhibitors as Anticancer Agents
Sarah Huff, Indrasena Reddy Kummetha, Lingzhi Zhang, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 16, pp. 10920-10937
Open Access | Times Cited: 46

Showing 1-25 of 46 citing articles:

The roles and implications of RNA m6A modification in cancer
Xiaolan Deng, Ying Qing, David Horne, et al.
Nature Reviews Clinical Oncology (2023) Vol. 20, Iss. 8, pp. 507-526
Closed Access | Times Cited: 152
Oxetanes in Drug Discovery Campaigns
Juan J. Rojas, James A. Bull
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 18, pp. 12697-12709
Open Access | Times Cited: 39
RNA modifications in cellular metabolism: implications for metabolism-targeted therapy and immunotherapy
Weiwei Liu, Si-Qing Zheng, Li Tian, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 27
Epigenetics-targeted drugs: current paradigms and future challenges
Wanlin Dai, Xinbo Qiao, Yuanyuan Fang, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 16
Rational Design of RNA Demethylase FTO Inhibitors with Enhanced Antileukemia Drug-Like Properties
Pan Xiao, Zongliang Duan, Zeyu Liu, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 14, pp. 9731-9752
Closed Access | Times Cited: 28
Discovery of Pyrazolo[1,5-a]pyrimidine Derivative as a Novel and Selective ALKBH5 Inhibitor for the Treatment of AML
Yingzhe Wang, Hongyu Li, Yan Zhang, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 23, pp. 15944-15959
Closed Access | Times Cited: 22
Small molecule inhibitors targeting m6A regulators
Guotai Feng, Yongya Wu, Yuan Hu, et al.
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 10
Role of PCIF1‐mediated 5′‐cap N6‐methyladeonsine mRNA methylation in colorectal cancer and anti‐PD‐1 immunotherapy
Lingling Wang, Lujing Wu, Zhouting Zhu, et al.
The EMBO Journal (2022) Vol. 42, Iss. 2
Open Access | Times Cited: 32
Emerging roles of m6A RNA modification in cancer therapeutic resistance
Weiwei Liu, Zhongyuan Zhang, Fei Wang, et al.
Experimental Hematology and Oncology (2023) Vol. 12, Iss. 1
Open Access | Times Cited: 17
RNA m6A modification in ferroptosis: implications for advancing tumor immunotherapy
Jun-Xiao Shi, Zhichao Zhang, Hao-zan Yin, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 5
RNA modifications in cancer
Han Wu, Shi Chen, Xiang Li, et al.
MedComm (2025) Vol. 6, Iss. 1
Open Access
Discovery of maleimide derivatives as m6A demethylase ALKBH5 inhibitors
Luxia Liang, Wenliang Fei, Yingzhe Wang, et al.
Bioorganic & Medicinal Chemistry (2025), pp. 118083-118083
Closed Access
Epitranscriptomics in the Glioma Context: A Brief Overview
Pablo Santamarina‐Ojeda, Agustín F. Fernández, Mario F. Fraga
Cancers (2025) Vol. 17, Iss. 4, pp. 578-578
Open Access
m6A regulator-based molecular classification and hub genes associated with immune infiltration characteristics and clinical outcomes in diffuse gliomas
Jie Lu, Siyu Chen, Wanming Hu, et al.
BMC Medical Genomics (2025) Vol. 18, Iss. 1
Open Access
A patenting perspective of fat mass and obesity associated protein (FTO) inhibitors: 2017-present
Ze Dong, Yue Huang, Wenyang Xia, et al.
Expert Opinion on Therapeutic Patents (2025)
Closed Access
Targeting RNA modifications with pharmacological agents: New frontiers in cancer therapy
Angel Guan, Justin Wong
Cancer Medicine (2024) Vol. 13, Iss. 7
Open Access | Times Cited: 4
Clinical Perspectives in Epitranscriptomics
Eloy Santos-Pujol, Carlos Quero-Dotor, Manel Esteller
Current Opinion in Genetics & Development (2024) Vol. 87, pp. 102209-102209
Open Access | Times Cited: 4
Methylation modifications in tRNA and associated disorders: Current research and potential therapeutic targets
Zhijing Wu, Ruixin Zhou, Baizao Li, et al.
Cell Proliferation (2024) Vol. 57, Iss. 9
Open Access | Times Cited: 4
The Functional Role and Regulatory Mechanism of FTO m6A RNA Demethylase in Human Uterine Leiomyosarcoma
Qiwei Yang, Ayman Al‐Hendy
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 9, pp. 7957-7957
Open Access | Times Cited: 11
m6A mRNA Modifications in Glioblastoma: Emerging Prognostic Biomarkers and Therapeutic Targets
Gloria S. Xie, Hope Richard
Cancers (2024) Vol. 16, Iss. 4, pp. 727-727
Open Access | Times Cited: 3
Structure‐Activity Relationships of 2‐(Arylthio)benzoic Acid FTO Inhibitors
Chao Guo Yan, Qian Zhang, Pan Xiao, et al.
Israel Journal of Chemistry (2024) Vol. 64, Iss. 3-4
Closed Access | Times Cited: 3
Emerging Roles and Mechanisms of RNA Modifications in Neurodegenerative Diseases and Glioma
Ami Kobayashi, Yosuke Kitagawa, Ali M. Nasser, et al.
Cells (2024) Vol. 13, Iss. 5, pp. 457-457
Open Access | Times Cited: 3
N6-methyladenosine (m6A) methylation in kidney diseases: Mechanisms and therapeutic potential
Yuting Sun, De Jin, Ziwei Zhang, et al.
Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms (2023) Vol. 1866, Iss. 4, pp. 194967-194967
Open Access | Times Cited: 9
Applications of oxetanes in drug discovery and medicinal chemistry
G. Huang, Devon G. Hucek, Tomasz Cierpicki, et al.
European Journal of Medicinal Chemistry (2023) Vol. 261, pp. 115802-115802
Open Access | Times Cited: 9
The role of N6-methyladenosine (m6A) in kidney diseases
Luling You, Zhongyu Han, Hao Chen, et al.
Frontiers in Medicine (2023) Vol. 10
Open Access | Times Cited: 9
Page 1 - Next Page

Scroll to top